• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    EVP, Chief Regulatory Officer Henrich Jill sold $7,410 worth of shares (1,059 units at $7.00), decreasing direct ownership by 5% to 18,679 units (SEC Form 4)

    3/5/25 5:16:33 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Henrich Jill

    (Last) (First) (Middle)
    C/O ATARA BIOTHERAPEUTICS, INC.
    1280 RANCHO CONEJO BOULEVARD

    (Street)
    THOUSAND OAKS CA 91320

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Atara Biotherapeutics, Inc. [ ATRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, Chief Regulatory Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/03/2025 S(1) 1,059 D $6.997(2) 18,679(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
    2. The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 3, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
    3. This amount includes 360 shares purchased under the Issuer's Employee Stock Purchase Plan on November 29, 2024.
    /s/ John Chao, Attorney-in-Fact for Jill Henrich 03/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATRA

    DatePrice TargetRatingAnalyst
    11/9/2023Outperform → In-line
    Evercore ISI
    11/9/2023Buy → Neutral
    H.C. Wainwright
    11/9/2023$31.00 → $1.00Buy → Neutral
    Mizuho
    7/20/2022$8.00 → $3.00Neutral → Sell
    Citigroup
    7/13/2022$10.00Overweight → Neutral
    JP Morgan
    7/13/2022$16.00 → $5.00Buy → Hold
    Stifel
    5/10/2022$15.00 → $8.00Buy → Neutral
    Citigroup
    1/3/2022$26.00 → $27.00Overweight
    JP Morgan
    More analyst ratings

    $ATRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Adiumentum Capital Fund I Lp was granted 75,572 shares (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      5/16/25 6:26:21 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Grant-Huerta Yanina claimed ownership of 39,285 shares (SEC Form 3)

      3 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      4/10/25 7:14:26 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Former EVP, CFO & COO Hyllengren Eric J

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      4/2/25 7:54:05 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/14/24 6:10:20 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/14/24 4:17:31 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/12/24 1:29:52 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Atara Biotherapeutics Inc.

      SCHEDULE 13D/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      5/16/25 6:28:02 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Atara Biotherapeutics Inc.

      8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

      5/16/25 5:26:51 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Atara Biotherapeutics Inc.

      SCHEDULE 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      5/15/25 9:00:22 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Atara Biotherapeutics downgraded by Evercore ISI

      Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line

      11/9/23 9:00:28 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral

      11/9/23 7:32:43 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded Atara Biotherapeutics from Buy to Neutral and set a new price target of $1.00 from $31.00 previously

      11/9/23 6:45:52 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

      5/16/25 8:50:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

      Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives Atara has entered into an underwriting agreement for an offering with expected gross proceeds of $16 million that Atara believes is sufficient to fund the ongoing activities required to achieve potential BLA approval Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Ba

      5/15/25 8:35:00 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics Announces Pricing of $16 Million Offering

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6099 per pre-funded warrant share in an underwritten registered direct offering to a limited number of existing institutional investors, including entities affiliated with Adiumentum Capital Management, EcoR1 Capital, Panacea Venture and Redm

      5/15/25 8:30:00 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gallagher Carol Giltner bought $68,214 worth of shares (270,000 units at $0.25), increasing direct ownership by 143% to 459,418 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/15/23 5:07:08 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dobmeier Eric bought $101,340 worth of shares (446,825 units at $0.23), increasing direct ownership by 384% to 563,325 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/14/23 6:27:14 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Heiden William K bought $25,330 worth of shares (100,000 units at $0.25), increasing direct ownership by 92% to 209,000 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/14/23 6:29:04 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Leadership Updates

    Live Leadership Updates

    See more

    $ATRA
    Financials

    Live finance-specific insights

    See more
    • Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

      5/16/25 8:50:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

      Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

      3/23/22 7:30:00 AM ET
      $ATRA
      $NTRA
      $TVTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial laun

      8/9/21 4:01:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w

      11/5/24 4:01:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

      Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),

      11/1/23 8:30:00 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At

      8/1/23 4:01:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care